Skip to main content

Hemoglobinopathies

1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
deferasiroxPhase 41 trial
Active Trials
NCT00673608Completed118Est. Sep 2011
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Non applicable, is a patient registryN/A1 trial
Active Trials
NCT06831799Completed684Est. Dec 2023
SOPHiA GENETICS
SOPHiA GENETICSMA - Boston
1 program
Non applicable, is a patient registryN/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
YOLT-204N/A1 trial
Active Trials
NCT07774351Not Yet Recruiting30Est. Apr 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Sandozdeferasirox
UNION therapeuticsYOLT-204
Heidelberg PharmaNon applicable, is a patient registry

Clinical Trials (3)

Total enrollment: 832 patients across 3 trials

NCT00673608Sandozdeferasirox

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Start: Nov 2007Est. completion: Sep 2011118 patients
Phase 4Completed
NCT07774351UNION therapeuticsYOLT-204

A Clinical Exploratory Study of YOLT-204 in the Treatment of Hemoglobinopathies

Start: Sep 2026Est. completion: Apr 202830 patients
N/ANot Yet Recruiting
NCT06831799Heidelberg PharmaNon applicable, is a patient registry

ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19

Start: Apr 2020Est. completion: Dec 2023684 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.